1
40
4
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.ijid.2012.01.003" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.ijid.2012.01.003</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
E321-E331
Issue
5
Volume
16
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza
Publisher
An entity responsible for making the resource available
International Journal of Infectious Diseases
Date
A point or period of time associated with an event in the lifecycle of the resource
2012
2012-05
Subject
The topic of the resource
human; pneumonia; Infectious Diseases; pneumonia; Influenza; community-acquired pneumonia; bacterial; randomized controlled-trial; streptococcus-pneumoniae; Influenza; virus; respiratory-tract; a h1n1 virus; Antibacterial agents; Antiviral agents; asian influenza; bacteremic pneumococcal; hong-kong influenza; Influenza A; pandemic; pregnant-women
Creator
An entity primarily responsible for making the resource
Metersky M L; Masterton R G; Lode H; File T M; Babinchak T
Description
An account of the resource
Post-influenza bacterial pneumonia is a major cause of morbidity and mortality associated with both seasonal and pandemic influenza virus illness. However, despite much interest in influenza and its complications in recent years, good clinical trial data to inform clinicians in their assessment of treatment options are scant. This paucity of evidence needs to be addressed urgently in order to improve guidance on the management of post-influenza bacterial pneumonia. The objectives of the current article are to evaluate the emergence of the 2009 H1N1 influenza pandemic and use this information as background for an in-depth review of the epidemiology of bacterial pneumonia complicating influenza, to review the bacterial pathogens most likely to be associated with post-influenza bacterial pneumonia, and to discuss treatment considerations in these patients. When determining optimal management approaches, both antiviral and antibacterial agents should be considered, and their selection should be based upon a clear understanding of how their mechanisms of action intervene in the pathogenesis of post-influenza acute bacterial pneumonia. (C) 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.ijid.2012.01.003" target="_blank" rel="noreferrer noopener">10.1016/j.ijid.2012.01.003</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article or Conference Abstract Publication
2012
a h1n1 virus
Antibacterial agents
Antiviral agents
asian influenza
Babinchak T
bacteremic pneumococcal
Bacterial
Community-acquired pneumonia
File T M
hong-kong influenza
Human
Infectious Diseases
Influenza
Influenza A
International Journal of Infectious Diseases
Journal Article or Conference Abstract Publication
Lode H
Masterton R G
Metersky M L
pandemic
Pneumonia
pregnant-women
randomized controlled-trial
respiratory-tract
streptococcus-pneumoniae
virus
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1086/432063" target="_blank" rel="noreferrer noopener">http://doi.org/10.1086/432063</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
554-556
Issue
4
Volume
41
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: Results from the CAPO International Cohort Study
Publisher
An entity responsible for making the resource available
Clinical Infectious Diseases
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
2005-08
Subject
The topic of the resource
therapy; Infectious Diseases; Microbiology; Immunology
Creator
An entity primarily responsible for making the resource
Christensen D; Feldman C; Rossi P; Marrie T; Blasi F; Luna C; Fernandez P; Porras J; Martinez J; Weiss K; Levy G; Lode H; Gross P; File T; Invest Capo
Description
An account of the resource
In a case-control study, outcomes for 58 human immunodeficiency virus (HIV)-positive patients with community-acquired pneumonia ( CAP) were compared with outcomes for 174 HIV-negative patients with CAP. No differences were found in the time to clinical stability, the length of hospitalization, and mortality. Clinical outcomes for hospitalized patients with CAP may not be influenced by HIV infection.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1086/432063" target="_blank" rel="noreferrer noopener">10.1086/432063</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article or Conference Abstract Publication
2005
Blasi F
Christensen D
Clinical Infectious Diseases
Feldman C
Fernandez P
File T
Gross P
Immunology
Infectious Diseases
Invest Capo
Journal Article or Conference Abstract Publication
Levy G
Lode H
Luna C
Marrie T
Martinez J
Microbiology
Porras J
Rossi P
therapy
Weiss K
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1378/chest.125.5.1888" target="_blank" rel="noreferrer noopener">http://doi.org/10.1378/chest.125.5.1888</a>
Pages
1888–1901
Issue
5
Volume
125
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Chest
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-05
Subject
The topic of the resource
Antibiotics; United States; Canada; Europe; Comparative Studies; Practice Guidelines; Drug Resistance; Pneumonia; Microbial; Antiinfective Agents; Community-Acquired Infections – Drug Therapy; Bacterial – Drug Therapy; Antibiotics – Administration and Dosage; Fluoroquinolone – Therapeutic Use; Macrolide – Therapeutic Use; Lactam – Therapeutic Use
Creator
An entity primarily responsible for making the resource
File T M Jr; Garau J; Blasi F; Chidiac C; Klugman K; Lode H; Lonks JR; Mandell L; Ramirez J; Yu V
Description
An account of the resource
Empiric antimicrobial prescribing for community-acquired pneumonia remains a challenge, despite the availability of treatment guidelines. A number of key differences exist between North American and European guidelines, mainly in the outpatient setting. The North American approach is to use initial antimicrobial therapy, which provides coverage for Streptococcus pneumoniae plus atypical pathogens. Europeans tend to focus on providing pneumococcal coverage with less emphasis on covering for an atypical pathogen. Ambulatory patients without comorbidity are more likely to receive macrolide therapy in North America, whereas in Europe these patients would probably receive a beta-lactam agent. Major issues that are fundamental to this difference include the importance of providing therapy for atypical pathogens and the clinical significance of macrolide-resistant S pneumoniae. Prospective data are required to evaluate which of these two approaches offers clinical superiority.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1378/chest.125.5.1888" target="_blank" rel="noreferrer noopener">10.1378/chest.125.5.1888</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2004
Antibiotics
Antibiotics – Administration and Dosage
Antiinfective Agents
Bacterial – Drug Therapy
Blasi F
Canada
Chest
Chidiac C
Community-Acquired Infections – Drug Therapy
Comparative Studies
Department of Internal Medicine
Drug Resistance
Europe
File T M Jr
Fluoroquinolone – Therapeutic Use
Garau J
Klugman K
Lactam – Therapeutic Use
Lode H
Lonks JR
Macrolide – Therapeutic Use
Mandell L
Microbial
NEOMED College of Medicine
Pneumonia
Practice Guidelines
Ramirez J
United States
Yu V
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1179/joc.2000.12.4.314" target="_blank" rel="noreferrer noopener">http://doi.org/10.1179/joc.2000.12.4.314</a>
Pages
314–325
Issue
4
Volume
12
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group.
Publisher
An entity responsible for making the resource available
Journal of chemotherapy (Florence, Italy)
Date
A point or period of time associated with an event in the lifecycle of the resource
2000
2000-08
Subject
The topic of the resource
*Fluoroquinolones; 80 and over; Acute-Phase Reaction; Adult; Aged; Amoxicillin/pharmacology/therapeutic use; Anti-Infective Agents/adverse effects/pharmacology/*therapeutic use; Bronchitis/*drug therapy; Chronic Disease; Clavulanic Acid/pharmacology/therapeutic use; Combination/pharmacology/*therapeutic use; Double-Blind Method; Drug Therapy; Female; Gemifloxacin; Haemophilus influenzae/drug effects; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moraxella (Branhamella) catarrhalis/drug effects; Multicenter Studies as Topic; Naphthyridines/adverse effects/pharmacology/*therapeutic use; Streptococcus pneumoniae/drug effects; Treatment Outcome
Creator
An entity primarily responsible for making the resource
File T; Schlemmer B; Garau J; Lode H; Lynch S; Young C
Description
An account of the resource
Six hundred patients were evaluated in this randomized, double-blind, double-dummy, multicenter, parallel-group study comparing the efficacy and safety of gemifloxacin (320 mg once-daily for 5 days) and amoxicillin/clavulanate (500/125 mg three-times daily for 7 days) for the treatment of acute exacerbations of chronic bronchitis (AECB). Of note, more than 90% of study participants had stage 2 disease at study entry. The two drugs were found to be equally effective, with clinical success rates of 93.6% for gemifloxacin and 93.2% on amoxicillin/clavulanate (95% CI -3.9 to 4.6). Bacteriological success rates favored gemifloxacin (90.9% compared with 79.5% for amoxicillin/clavulanate; 95% CI -3.3 to 26.0); however, this difference was not statistically significant. Gemifloxacin and amoxicillin/clavulanate were both well tolerated. In summary, gemifloxacin was found to be well tolerated and effective for the treatment of AECB, suggesting it is well suited for empirical treatment of this common respiratory condition in the current clinical environment.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1179/joc.2000.12.4.314" target="_blank" rel="noreferrer noopener">10.1179/joc.2000.12.4.314</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Fluoroquinolones
2000
80 and over
Acute-Phase Reaction
Adult
Aged
Amoxicillin/pharmacology/therapeutic use
Anti-Infective Agents/adverse effects/pharmacology/*therapeutic use
Bronchitis/*drug therapy
Chronic Disease
Clavulanic Acid/pharmacology/therapeutic use
Combination/pharmacology/*therapeutic use
Department of Internal Medicine
Double-Blind Method
Drug Therapy
Female
File T
Garau J
Gemifloxacin
Haemophilus influenzae/drug effects
Humans
Journal of chemotherapy (Florence, Italy)
Lode H
Lynch S
Male
Microbial Sensitivity Tests
Middle Aged
Moraxella (Branhamella) catarrhalis/drug effects
Multicenter Studies as Topic
Naphthyridines/adverse effects/pharmacology/*therapeutic use
NEOMED College of Medicine
Schlemmer B
Streptococcus pneumoniae/drug effects
Treatment Outcome
Young C